A cost-utility analysis of secondary prophylaxis for variceal hemorrhage

American Journal of Gastroenterology

Volumn 99, Issue 7, 2004, Pages 1274-1288

  Rubenstein, Joel H ^a   Eisen, Glenn M ^b   Inadomi, John M ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NITRATE;

ARTICLE; COST UTILITY ANALYSIS; ENDOSCOPIC BAND LIGATION; ENDOSCOPIC SURGERY; ESOPHAGUS VARICES BLEEDING; HEPATIC ENCEPHALOPATHY; HUMAN; LITERATURE; LIVER CIRRHOSIS; OBSERVATION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; RISK; SECONDARY PREVENTION; ADOLESCENT; ADULT; CHILD; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; ESOPHAGUS VARICES; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT ATTITUDE; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MARKOV CHAINS; MIDDLE AGED; ODDS RATIO; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 3843129710     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.04153.x     Document Type: Article

References (90)

1. Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. Hepatology 1997;25:63-70.
2. Garden OJ, Mills PR, Birnie GG, et al. Propranolol in the prevention of recurrent variceal hemorrhage in cirrhotic patients: A controlled trial. Gastroenterology 1990;98:185-90.
3. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
4. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Bailliere's Clin Gastroenterol 1997;11:243-55.
5. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566-73.
6. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: A multicenter, cohort study. Am J Gastroenterol 2003;98:653-9.
7. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92:1081-91.
8. Bernard B, Lebrec D, Mathurin P, et al. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis. J Hepatol 1997;26:312-24.
9. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995;123:280-7.
10. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55.
11. Lo G-H, Chen W-C, Chen M-H, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002;123:728-34.
12. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013-9.
13. Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999;30:612-22.
14. Lo GH, Lai KH, Cheng JS, et al. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: A prospective, randomized trial. Hepatology 2000;32:461-5.
15. Pomier-Layrargues G, Villeneuve JP, Deschenes M, et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: A randomised trial. Gut 2001;48:390-6.
16. Russo MW, Zacks SL, Sandler RS, et al. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology 2000;31:358-63.
17. Gatta A, Merkel C, Sacerdoti D, et al. Nadolol for prevention of variceal rebleeding in cirrhosis: A controlled clinical trial. Digestion 1987;37:22-8.
18. Rossi V, Cales P, Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: Prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991;12:283-9.
19. Lebrec D, Poynard T, Hillon P, et al. Propranolol for the prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med 1981;305:137l-4.
20. Burroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983;309:1539-42.
21. Colombo M, De Franchis R, Tommasini M, et al. Beta-blockade prevents recurrent gastrointestinal bleeding in well-compensated patients with alcoholic cirrhosis: A multicenter randomized controlled trial. Hepatology 1989;9:433-8.
22. Villeneuve J-P, Pomier-Layrargues G, Infante-Rivard C, et al. Propranolol for the prevention of recurrent variceal hemorrhage: A controlled trial. Hepatology 1986;6:1239-43.
23. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-45.
24. Jalan R, Forrest EH, Stanley AJ, et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology 1997;26:1115-22.
25. Sauer P, Theilmann L, Stremmel W, et al. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology 1997;113:1623-31.
26. Gulberg V, Schepke M, Geigenberger G, et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: A randomized, controlled trial. Scand J Gastroenterol 2002;37:338-43.
27. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
28. Company ME. Drug topics red book. Montvale, NJ: Medical Economics Company, 2002.
29. Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-83.
30. Chong CAKY, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-8.
31. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic Hepatitis C. Ann Intern Med 1997;127:855-65.
32. Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic Hepatitis C: Risks, benefits, and costs. JAMA 1998;280:2088-93.
33. Chapman RH, Stone PW, Sandberg EA, et al. A Comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000;20:451-67.
34. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7.
35. Sonnenberg A, Inadomi JM, Bauerfeind P. Reliability block diagrams to model disease management. Med Decis Making 1999;19:180-5.
36. Sonnenberg A, Inadomi JM. Reliability block diagrams to model the management of colorectal cancer. Dig Dis Sci 1999;44:314-21.
37. Poynard T, Lebrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding. Hepatology 1987;7:447-51.
38. Luca A, D'Amico G, La Galla R, et al. TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials. Radiology 1999;212:411-21.
39. Burroughs AK, Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: Randomized trials for secondary prophylaxis of variceal bleeding: An updated meta-analysis. Scand J Gastroenterol 2002;37:249-52.
40. Andersen PK, Esbjerg S, Sorensen TI. Multi-state models for bleeding episodes and mortality in liver cirrhosis. Stat Med 2000;19:587-99.
41. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: A meta-analytic review. Hepatology 1995;22:332-54.
42. Rosellini SR, Miglio F. Beta-blockers for the prevention of variceal haemorrhage in patients with cirrhosis: An updated meta-analysis of randomized controlled trials. Ital J Gastroenterol 1991;23:408-15.
43. Thomsen BL, Sorensen TIA. Project CEVS: Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices. J Hepatol 1998;28:107-14.
44. Escorsell A, Banares R, Garcia-Pagan JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. Hepatology 2002;35:385-92.
45. Hoyert DL, Arias E, Smith BL, et al. Deaths: Final data for 1999. Natl Vital Stat Rep 2001;49:1-114.
46. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
47. Laine L, El-Newihi HM, Migikovsky B, et al. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices. Ann Intern Med 1993;119:1-7.
48. Silverstein FE, Gilbert DA, Tedesco FJ, et al. The national ASGE survey on upper gastrointestinal bleeding. Gastroint Endos 1981;27:73-102.
49. Rossle M, Siegerstetter V, Huber M, et al. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art. Liver 1998;18:73-89.
50. Pagliaro L, Burroughs AK, Sorensen TIA, et al. Therapeutic controversies and randomised controlled trials (RCTs): Prevention of bleeding and rebleeding in cirrhosis. Gastroenterol Int 1989;2:71-84.
51. Del Olmo JA, Pena A, Serra MA, et al. Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis. J Hepatol 2000;32:19-24.
52. Pagliaro L, D'Amico G, Pasta L, et al. Efficacy and efficiency of therapy in portal hypertension. In: Baveno International Consensus Workshop on Definitions M, and Therapeutic Strategies, Portal hypertension II: Proceedings of the Second Baveno International Consensus Workshop. Cambridge, MA: Blackwell Science, 1996:159-79.
53. Morgan AG, Clamp SE. OMGE international upper gastrointestinal bleeding survey, 1978-1986. Scand J Gastroenterol 1988;23:51-8.
54. Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. Ann Intern Med 1997;126:849-57.
55. Cabrera J, Maynar M, Granados R, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996;110:832-9.
56. Rossle M, Deibert P, Haag K, et al. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet 1997;349:1043-9.
57. Garcia-Villarreal L, Martinez-Lagares F, Sierra A, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage. Hepatology 1999;29:27-32.
58. Merli M, Salerno F, Riggio O, et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology 1998;27:48-53.
59. Sauer P, Benz C, Theilman L, et al. Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: Final results of a randomized study. Gastroenterology 1998;114:A604.
60. Cello JP, Ring EJ, Olcott EW, et al. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage. Ann Intern Med 1997;126:858-65.
61. Pagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: Natural history. In: Groszmann RJ, ed. Portal hypertension: Pathophysiology and treatment. Boston: Blackwell Scientific, 1994:77-92.
62. Cortez-Pinto H, Abrantes A, Esteves AV, et al. Long-term prognosis of patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J Gastroenterol 1989;84:1239-43.
63. Cooper GS, Bellamy P, Dawson NV, et al. A prognostic model for patients with end-stage liver disease. Gastroenterology 1997;113:1278-88.
64. Schlichting P, Christensen E, Fauerholdt L, et al. Main causes of death in cirrhosis. Scand J Gastroenterol 1983;18:881-8.
65. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-75.
66. Tait IS, Krige JEJ, Terblanche J. Endoscopic band ligation of oesophageal varices. Br J Surg 1999;86:437-46.
67. Young MF, Sanowski RA, Rasche R. Comparison and characterization of ulcerations induced by endoscopic ligation of esophageal varices versus endoscopic sclerotherapy. Gastrointest Endosc 1993;39:119-22.
68. Cipolletta L, Bianco MA, Rotondano G, et al. Argon plasma coagulation prevents variceal recurrence after band ligation of esophageal varices: Preliminary results of a prospective randomized trial. Gastrointest Endosc 2002;56:467-71.
69. Hou M-C, Lin H-C, Lee F-Y, et al. Recurrence of esophageal varices following endoscopic treatment and its impact on rebleeding: Comparison of sclerotherapy and ligation. J Hepatol 2000;32:202-8.
70. Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices : Influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997;26:826-32.
71. Goff JS, Reveille RM, Stiegmann GV. Three years experience with endoscopic variceal ligation for treatment of bleeding varices. Endoscopy 1992;24:401-4.
72. Gimson AES, Ramage JK, Panos MZ, et al. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993;342:391-4.
73. Stiegmann GV, Goff JS, Michaletz-Onody PA, et al. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med 1992;326:1527-32.
74. Lo G-H, Lai K-H, Cheng J-S, et al. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices. Hepatology 1995;22:466-71.
75. Quine MA. Prospective audit of upper gastrointestinal endoscopy in two regions of England: Safety, staffing, and sedation methods. Gut 1995;36:462-7.
76. Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications: Results of the 1974 American Society for Gastrointestinal Endoscopy survey. JAMA 1976;235:928-30.
77. Arrowsmith JB, Gerstman BB, Fleischer DE, et al. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991;37:421-7.
78. Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: A comprehensive review. Radiographics 1993;13:1185-210.
79. Stanley AJ, Jalan R, Forrest EH, et al. Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: Results in 130 patients. Gut 1996;39:479-85.
80. Nazarian GK, Ferral H, Bjarnason H, et al. Effect of transjugular intrahepatic portosystemic shunt on quality of life. Am J Roentgenol 1996;167:963-9.
81. Sahagun G, Benner KG, Saxon R, et al. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage. Am J Gastroenterol 1997;92:1444-52.
82. Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997;112:889-98.
83. LaBerge JM, Somberg KA, Lake JR, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: Results in 90 patients. Gastroenterology 1995;108:1143-51.
84. Canizares RB, Rodriguez-Laiz JM, Martin MC, et al. Transjugular intrahepatic portosystemic shunt with the Strecker stent for control of refractory acute and chronic variceal bleeding: Results in 50 patients. Scand J Gastroenterol 1996;31:285-93.
85. Lind CD, Malisch TW, Chong WK, et al. Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. Gastroenterology 1994;106:1277-83.
86. Rossle M, Siegerstetter V, Olschewski M, et al. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001;96:3379-83.
87. Kanterman RY, Darcy MD, Middleton WD, et al. Doppler sonography findings associated with transjugular intrahepatic portosystemic shunt malfunction. Am J Roentgenol 1997;168:467-72.
88. Dodd GD III, Zajko AB, Orons PD, et al. Detection of transjugular intrahepatic portosystemic shunt dysfunction: Value of duplex Doppler sonography. Am J Roentgenol 1995;164:1119-24.
89. Chong WK, Malisch TA, Mazer MJ, et al. Transjugular intrahepatic portosystemic shunt: US assessment with maximum flow velocity. Radiology 1993;189.
90. Viamonte M Jr, LePage J, Lunderquist A, et al. Selective catheterization of the portal vein and its tributaries. Preliminary report. Radiology 1975;114:457-60.